UB Paderborn / Katalog / Suche / in CDI

1 – 16 von 16

Sortiert nach

The Traditional Cosmos and the New World

MLN, 2003-03, Vol.118 (2), p.363-392

Kupper, Joachim

2003

Volltextzugriff (PDF)

The landscape of genomic alterations across childhood cancers

Nature (London), 2018-03, Vol.555 (7696), p.321-327

2018

Volltextzugriff (PDF)

Inheritance of Gene Density-Related Higher Order Chromatin Arrangements in Normal and Tumor Cell Nuclei

The Journal of cell biology, 2003-09, Vol.162 (5), p.809-820

2003

Volltextzugriff (PDF)

Endovascular thrombectomy for basilar artery occlusion stroke: Analysis of the German Stroke Registry‐Endovascular Treatment

European journal of neurology, 2023-05, Vol.30 (5), p.1293-1302

2023

Volltextzugriff (PDF)

Neladenoson Bialanate Hydrochloride: A Prodrug of a Partial Adenosine A 1 Receptor Agonist for the Chronic Treatment of Heart Diseases

ChemMedChem, 2017-05, Vol.12 (10), p.728-737

2017

Volltextzugriff (PDF)

Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis

Journal of rheumatology, 2009-04, Vol.36 (4), p.801

2009

Volltextzugriff (PDF)

Implantation meets intervention: reopening of a thrombotic ostial occlusion of coronary sinus by angioplasty achieved improvement of cardiac venous drainage and allowed transvenous CRT implantation

Clinical research in cardiology, 2017-12, Vol.106 (12), p.1033-1039

2017

Volltextzugriff (PDF)

A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis

Journal of rheumatology, 2002-11, Vol.29 (11), p.2288

2002

Volltextzugriff (PDF)

Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab

Rheumatology (Oxford, England), 2015-07, Vol.54 (7), p.1210-1219

2015

Volltextzugriff (PDF)

Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study

Critical care medicine, 2001-04, Vol.29 (4), p.765-769

2001

Volltextzugriff (PDF)

An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status

Clinical rheumatology, 2008-08, Vol.27 (8), p.1021-1028

2008

Volltextzugriff (PDF)

The effect of third-party reporting on adoption of evidence-based mesalazine regimens in ulcerative colitis: An observational study

Journal of Crohn's and colitis, 2013-05, Vol.7 (4), p.e125-e132

2013

Volltextzugriff (PDF)

Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis

Arthritis research & therapy, 2009-01, Vol.11 (4), p.R124-R124

2009

Volltextzugriff (PDF)

Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: Results of a twelve‐week randomized, double‐blind, placebo‐controlled trial followed by an open‐label extension up to week fifty‐two

Arthritis and rheumatism, 2008-07, Vol.58 (7), p.1981-1991

2008

Volltextzugriff (PDF)

Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double‐blind, placebo‐controlled trial

Arthritis and rheumatism, 2006-07, Vol.54 (7), p.2136-2146

2006

Volltextzugriff (PDF)

Adalimumab reduces spinal symptoms in active ankylosing spondylitis: Clinical and magnetic resonance imaging results of a fifty‐two–week open‐label trial

Arthritis and rheumatism, 2006-02, Vol.54 (2), p.678-681

2006

Volltextzugriff (PDF)

1 – 16 von 16

Suche als RSS-Feed

Aktive Filter

ThemaHumans

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(13)
Mit Volltextzugriff
(13)

Publikationsform

Artikel
(16)

Sprache

Englisch
(16)
Japanisch
(3)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The Traditional Cosmos and the New World

The landscape of genomic alterations across childhood cancers

Inheritance of Gene Density-Related Higher Order Chromatin Arrangements in Normal and Tumor Cell Nuclei

Endovascular thrombectomy for basilar artery occlusion stroke: Analysis of the German Stroke Registry‐Endovascular Treatment

Neladenoson Bialanate Hydrochloride: A Prodrug of a Partial Adenosine A 1 Receptor Agonist for the Chronic Treatment of Heart Diseases

Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis

Implantation meets intervention: reopening of a thrombotic ostial occlusion of coronary sinus by angioplasty achieved improvement of cardiac venous drainage and allowed transvenous CRT implantation

A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis

Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab

Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study

An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status

The effect of third-party reporting on adoption of evidence-based mesalazine regimens in ulcerative colitis: An observational study

Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis

Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: Results of a twelve‐week randomized, double‐blind, placebo‐controlled trial followed by an open‐label extension up to week fifty‐two

Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double‐blind, placebo‐controlled trial

Adalimumab reduces spinal symptoms in active ankylosing spondylitis: Clinical and magnetic resonance imaging results of a fifty‐two–week open‐label trial

Aktive Filter

Suchergebnisse filtern